INTRODUCTION
============

Sudden cardiac arrest (SCA) and sudden cardiac death (SCD) refer to the sudden collapse of cardiac activity with hemodynamic compromise, either due to sustained ventricular tachycardia (VT)/ventricular fibrillation (VF), asystole or pulseless electric activity (PEA). There are also non-cardiac etiologies for sudden circulatory collapse (Table**1**) \[[@R1]\]. The most common cause of cardiac arrest is acute or chronic coronary artery disease but various other cardiac and non-cardiac related diseases are also well recognised, as initially disputed (Table**1**). Sudden out of hospital cardiac arrest accounts for around 0.5 - 1 deaths per 1000 population every year \[[@R2]\]. In North America alone, more than 300.000 deaths per year are attributed to SCA \[[@R3]\]. The survival rate has remained very low for several decades, with only 8-10 % of patients surviving to hospital discharge and in many rural areas survival is dramatically less \[[@R4]\]. Survival and long-term functional outcome are closely related to the underlying cause such as initial rhythm.

RISK FACTORS FOR SUDDEN CARDIAC DEATH
=====================================

The high mortality associated with SCA emphasises the need for early identification of patients at risk. However, very little is known about risk factors. Since coronary artery disease is the most important cause of SCA, cardiovascular risk factors also increase the risk of OHCA and this is especially the case for diabetes and smoking but less so for obesity \[[@R8],[@R9]\].

However, our understanding of the relationship between acute myocardial ischemia and its most fatal immediateconsequence, cardiac arrhythmia, remains very limited. We know that ischemia alters repolarisation and it prolongs the QT interval \[[@R10]\]. The extent of QT prolongation during an acute coronary artery occlusion depends on the degree of collateralisation \[[@R10],[@R11]\]. Intriguingly, there is increasing evidence that the collateral circulation has a protective role during early ischemia. A study in 170 patients with acute anterior infarction showed lower incidence for malignant arrhythmias (defined as VF, VT or high degree atrioventricular (AV) block and lower mortality in patients with angiographically well-developed collaterals \[[@R12]\]. Furthermore, a well-developed collateral circulation has been associated with reduced risk for cardiac and all-cause mortality in patients with stable coronary artery disease in general \[[@R13]\].

ELECTROPHYSIOLOGICAL RISK ASSESSMENT
====================================

Testing of the electrical vulnerability to ventricular arrhythmia remains elusive. This is primarily due to the dynamic nature of the electrophysiological behavior of the myocardium. Although invasive electrophysiological testing to evaluate the inducibility of ventricular arrhythmia has been advocated, the validity of this approach is uncertain. Non-invasive investigations have been developed to estimate the susceptibility to arrhythmias \[[@R14]\]. These tests examine different aspects of myocardial electrophysiology as reflected on the surface electrocardiogram (ECG), namely change of autonomic function due to increased circulating catecholamines, delay in myocardial conduction, prolongation of repolarization and stretch-induced after-depolarisations.

The clinical usefulness of these tests is controversial. The highest diagnostic yield may be a combination of tests given the limited predictive value of each individual investigation \[[@R15]\].

THE RISK OF SCD IN ATHLETES
===========================

Overall, the risk of SCD is estimated to be between 1:50.000 and 1:300.000 in athletes over a 10-20 years period \[[@R16]-[@R18]\].

Due to their increased physical activity, athletes, and especially those involved in competitions, are at particular risk of SCA in the presence of conditions such as hypertrophic cardiomyopathy, abnormal origin of the coronary arteries, myocarditis, arrhythmic right ventricular cardiomyopathy (ARVC), mitral valve prolapse, aortic stenosis, coronary arteriosclerosis \[[@R19]\]. The European Society of Cardiology (ESC) has published guidelines for the pre-participation screening of young competitive athletes in 2005 \[[@R20]\]:

-   Complete personal and family history and physical examination

-   12 lead ECG

-   Any abnormal findings warrant further examination (e.g. echocardiography or cardiac magnetic resonance imaging (CMR)

-   Reevaluation after two years

Similarly, a family screening of patients who experienced unexplained OHCA has to be considered. An ECG and stress-testing, echocardiography or magnetic resonance imaging (MRI) but also genetic testing may be useful in this setting.

MANAGEMENT OF SCA
=================

The European Resuscitation Council (ERC) updated their guidelines on the treatment of SCA in 2010 \[[@R21]\]. The main changes compared to the 2005 guidelines in Basic Life Support (BLS) were the introduction of a compression/ventilation ratio of 30:2 as compared to 15:2 to optimize maintenance of circulation and reduce the "hands-off" periods. There is increasing evidence that continuous chest compressions ("hands-only cardio- pulmonary resuscitation (CPR) without ventilation, might not entail adverse consequences on neurologic outcome, at least within the first few minutes after SCA \[[@R22]\].

However, the debate on the ratio of chest compressions and ventilations during CPR and the continuous adaption of guidelines may have confused lay people and prevented them from performing CPR. Nose-to-mouth or mouth-to-mouth ventilation recommended during CPR may further deter people fearing infection. Moreover, the use of automated external defibrillators (AED) is clearly recommended.

It is a matter of an ongoing debate, whether CPR should be applied immediately or whether early defibrillation should be preferred in patients after SCA. While current guidelines advocate immediate defibrillation, both approaches seem to have comparable results and in patients with a cardiac arrest \>5 minutes, chest compressions before defibrillation may be superior \[[@R23]\].

Importantly, patient transfer with ongoing CPR results in reduced quality of chest compressions. However, with the new mechanical chest compression devices (e.g., LUCAS (Jolife, Lund, Sweden) and AutoPulse (Zoll Circulation, Chelmsford, Massachusetts, USA) adequate chest compression quality can be maintained during transport \[[@R24]\]. However, there is currently insufficient evidence for a clear advantage over manual chest compressions with regard to clinical outcomes when using the LUCAS device \[[@R25]\]. Similarly, the Circulation Improving Resuscitation Care (CIRC) trial assessing the effect of the AutoPulse automatic chest compression device in \>4000 OHCA patients failed to show a survival benefit. However, the data of this trial are not published yet.

The primary aim of post cardiac arrest return of spontaenous circulation (post-ROSC) care is to optimize cardio-cerebral recovery. In-hospital aims include maintaining cardiac output and cerebral perfusion, optimising systemic haemodynamics and minimising ischaemia-reperfusion injury \[[@R26]\]. The importance of optimal post-resuscitation care is highlighted in the recent 2010 International Liaison Committee on Resuscitation (ILCOR) Consensus on CPR Science with Treatment Recommendations (CoSTR) and ERC Guidelines \[[@R27],[@R28]\]. Table**2** gives an overview of a recommended diagnostic work-up of patients who survived SCA.

MANAGEMENT OF OHCA
==================

An updated Advanced Life Support (ALS) algorithm for medical professionals is shown in Fig. (**[1](#F1){ref-type="fig"}**).

ROLE OF HEART CATHETERIZATION AND PERCUTANEOUS INTERVENTION AFTER SCA
=====================================================================

Importantly, current guidelines recommend immediate referral of patients after OHCA to a cardiac centre with onsite cardiac catheterisation facilities in patients after SCA \[[@R21]\]. The decision by the pre-hospital emergency medical service (EMS) provider where to admit the patient after an OHCA is crucial. Several non-randomised observational studies have demonstrated survival benefit from early angiography post-OHCA compared to no coronary angiography or percutaneous coronary intervention (PCI) \[[@R29],[@R30]\]. However, other studies have also highlighted an increased complication risk if early angiography is performed in these patients \[[@R31]\]. In our view, although the role of immediate coronary angiography is controversial, substantial information on the coronary circulation can guide in-hospital management beyond coronary intervention. For example, in patients with cardiogenic shock, an intra-aortic balloon pump (IABP) or other support devices (e.g. Impella 2.5) can be inserted at this occasion to augment cardiac output \[[@R32]\].

Moreover, approximately 80% of OHCA presenting with VF or VT are cardiac in origin and these patients may benefit from an early PCI \[[@R33]\]. Studies are currently under way to determine whether patients who fail to achieve return of spontaneous circulation (ROSC) at the scene and who are suspected to have obstructive CAD may benefit from PCI whilst receiving continuous CPR \[[@R34]\]. Importantly, PCI plays a major role in the improved survival rates \[[@R35],[@R36]\]. In a study of 714 OHCA patients referred to a tertiary centre in Paris, 435 (61%) had no obvious extracardiac cause. This subgroup underwent early coronary angiography and 70% of those had at least one significant coronary lesion \[[@R30]\].

To facilitate decision making, an ECG should be recorded as soon as possible after ROSC to assess for ST-elevation or (new) LBBB \[[@R37]\]. However, the ECG has a limited accuracy in the setting of SCA. The absence of ST-segment elevation does not exclude the presence of critical coronary stenoses. In approximately 50% of OHCA survivors despite the absence of ST-segment elevation in the post-arrest ECG, a significant coronary artery stenosis can be found; \[[@R29],[@R30]\] However, even though these coronary artery stenoses were regarded "significant", it remains unclear whether these stenoses are actually the cause for the cardiac arrest and whether revascularising these lesions can improve the clinical outcome. Unfortunately, the evidence in this area is very scant, cardiac arrest patients have been excluded from most acute myocardial infarction trials, which has created a gap of evidence for these patients. While non-cardiac arrest patients with ST elevation infarctions clearly benefit from immediate angiography/ PCI, we lack data for patients after a cardiac arrest.

HYPOTHERMIA
===========

Based on experience with avalanche victims who had good neurological outcome despite very prolonged circulatory arrest under the circumstance of hypothermia, the concept of therapeutic hypothermia has been proposed in patients with OHCA. As to date, it is the only post-ROSC intervention shown to improve survival from OHCA \[[@R38]\]. Two major randomised clinical trials (the Hypothermia After Cardiac Arrest trial from Europe \[[@R39]\] and a smaller trial from Australia \[[@R40]\]) have demonstrated the efficacy of this intervention. The exact mechanism of the protective effects of mild therapeutic hypothermia (MTH) remains to be determined but probably includes a reduction of ischaemia-reperfusion injury and a reduction in oxidative stress. During cardiac arrest, brain tissue becomes ischaemic. Following ROSC, rapid re-oxygenation leads to oxygen free radical production, which can lead to secondary cell death. MTH has pleiotropic neuroprotective effects. MTH slows down cellular metabolism, altering biochemical and signaling pathways and reduces oxygen demand. Comatose (i.e., lack of meaningful response to verbal commands) adult patients with ROSC after out-of-hospital VF cardiac arrest should be cooled to 32°C to 34°C for at least 12 to 24 hours. MTH can also be considered following OHCA with non-shockable initial rhythms such as PEA or asystole but the benefit in these patients is less clear \[[@R28],[@R41]\].

Many questions surrounding MTH remain unanswered. The timing of initiation and the optimal duration of cooling are unclear. Should MTH be initiated pre-hospital or is it sufficient to start this therapy in hospital? Some experimental studies suggest that early cooling improves outcome; but a randomised clinical trial failed to show superiority for pre-hospital cooling versus in-hospital initiated cooling \[[@R42]\]. The time frame during which MTH can be initiated is unknown. The length of time MTH should be maintained is also uncertain. In the Australian trial patients were cooled for 12 hours \[[@R40]\], while in the Hypothermia After Cardiac Arrest (HACA) trial they were cooled for 24 hours \[[@R39]\]. Longer duration may be superior. \[[@R43]\]

The optimal cooling method is not yet clear \[[@R38]\]. External cooling methods include cold pads and cooling caps, whilst invasive cooling methods include cold intra-venous saline or intra-vascular cooling catheters. Recently, intra-nasal evaporative cooling has been shown to produce effective pre-hospital cooling \[[@R44]\]. However, 30 mL/kg of intravenous 4°C saline or Hartmann's solution is the simplest and most cost effective method for pre-hospital setting. The target core temperature is 33 ± 1°C. Intravascular devices have been shown to be effective in inducing and maintaining this target temperature; however, there can be delays in inserting the intravascular catheter and this is more invasive than other techniques. Surface cooling, using cooling blankets and ice packs to the axilla, groin and neck, has also been advocated. These devices are simple, require less operator experience, and are inexpensive, but initial cooling may be slower \[[@R45]\]. One study has shown that both intravascular and surface cooling are equivalent in their effectiveness to reach and maintain core temperatures \[[@R46]\], although another showed better temperature control with an intravascular device \[[@R47]\]. Whichever method is used, a feedback loop is advocated to ensure target temperature compliance and to prevent overcooling. Devices with feedback control also enable better control of rewarming (usually at 0.25^o^C/h).

Despite strong evidence and clear guideline recommendations, MTH is still under-used in some regions of the world. In a recent trial of an impedance threshold device for OHCA in the United States and Canada, just 48% of the 2289 enrolled patients admitted hospital were treated with therapeutic hypothermia \[[@R48]\]. On the other hand, in the UK 86% of intensive care units had implemented hypothermia by 2009 \[[@R49]\]. Lack of resources and cost of MTH are commonly cited as barriers to implementation, despite relatively cheap options being available.

However, in patients with MTH several side effects may occur. MTH may affect the coagulation cascade and platelet function, eventually leading to an increased bleeding risk \[[@R50],[@R51]\]. In case of bleeding, the patient should be rewarmed \>35°C body temperature. Moreover, leucocyte function may be decreased resulting in an increased risk for infections \[[@R39]\]. On the ECG, bradycardia and a prolongation of the QT interval may be detected \[[@R52]\]. In rare cases, severe arrhythmias are provoked by MTH. Further, due to renal side effects, the electrolyte balance may be altered and careful monitoring is mandatory \[[@R53],[@R54]\]. Additionally, the metabolisation of several drugs may be altered by MTH \[[@R54]\].

SECONDARY PREVENTION OF SCA
===========================

In patients who survived SCA, strategies are needed to prevent future, potentially fatal events. The mechanisms of death were evaluated in several studies. The main cause of death in these trials was low cardiac output due to progressive heart failure (45-50%), severe arrhythmia (20-35%) and non-cardiac related death (e.g. renal disease, ca. 20-30%) \[[@R55],[@R56]\]. Table**3.** refers to the European Society of Cardiology (ESC) guidelines on decision making on implantable cardioverter defibrillator (ICD) implantation for secondary prevention of SCA due to severe arrhythmia \[[@R57],[@R58]\]. Additional therapies including VT ablation or permanent antiarrhythmic therapy may be warranted in selected cases. However, as outlined previously severe arrhythmias are closely related to an impaired left ventricular function, and an optimal heart failure management will be mandatory in this patient population \[[@R59]\].

PROGNOSIS AFTER SCA
===================

The Time to defibrillation and other factors such as bystander CPR, has not improved over precise time \[[@R60]\]. The chain of survival (Fig.**2**) is changing over time and it is likely that it will soon include pre-hospital induction of hypothermia and early coronary intervention. Overall, such changes have increased the survival rate. In Sweden for instance, the survival rate after OHCA has doubled over the last years \[[@R61]\].

The prognosis after cardiac arrest is determined by several factors. In case of asystole or PEA as the initial rhythm, a prolonged cardiac arrest must be assumed and therefore only 10% of patients will survive until hospital admission \[[@R62],[@R63]\]. In contrast, outcome is much better in patients with ventricular arrhythmias, especially in those with a witnessed cardiac arrest \[[@R64]\]. In the vast majority of patients, ventricular fibrillation will not terminate spontaneously and the probability to survive will decline by 10% per minute of ongoing VF \[[@R65]\]. Ideally, a regular pulse is restored within 10 minutes of CPR \[[@R66]\].

In a study including 200 patients presenting with ventricular fibrillation and successful early defibrillation, 72% of patients survived until hospital admission. However, only 40% of these patients were discharged with no or mild neurologic impairments \[[@R64]\]. Therefore, angiography is often delayed until the neurological status of the patient can be determined accurately. Blood markers may help to estimate the impact of hypoxic brain injury, such as the levels of the protein "neurone specific enolase", "S-100" or "IL-8", although predictive value and accuracy varies widely in different studies \[[@R67],[@R68]\]. More precise tools to predict outcomes would help tremendously for optimal resource allocation \[[@R69]\].

CARDIAC ARREST CENTRES
======================

There is variation in outcome for OHCA patients depending on the hospital they are admitted to \[[@R70]\] and there is some evidence that mortality is lower among those admitted to intensive care units (ICUs) that treat a high volume of post-cardiac arrest patients \[[@R71]\]. A specialised multidisciplinary team approach to post-resuscitation care is essential. Post-resuscitation care is started by the EMS on scene and in some systems this may include pre-hospital induction of hypothermia. It is important to designate specific and clear roles to each team involved in the care and management of OHCA patients (emergency medicine, critical care, cardiology, neurology).

Trauma-centres have dramatically improved the outcomes of severely-injured patients. This model might be applicable to other medical conditions such as OHCA or stroke. Based on this premise, regionalised, coordinated resuscitation centres to care for post-OHCA patients has been proposed \[[@R72]\]. EMS providers should transport patients to those hospitals that are best suited for caring for OHCA victims - such hospitals would provide therapeutic hypothermia, 24/7 access to PCI facilities and availability of dedicated neurological investigations \[[@R72]\].

CONCLUSIONS
===========

There have been multiple recent advances in the care of OHCA patients which may have a synergistic effect. The development of cardiac arrest centres, post-OHCA management protocols, further advances in therapeutic hypothermia and primary percountaneous intervention (PPCI) in post-OHCA are likely to further improve outcomes in the future. We are moving away from the perception that survival of OHCA victims is a fortunate rare event towards a renewed sense that OHCA is often a treatable event with an increasing chance for neurologically intact survival.
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ABBREVIATIONS
=============

ROSC

:    =  Return of Spontaneous Circulation

ALS

:    =  Advanced Life Support

ARVC

:    =  Arrhythmic Right Ventricular Cardiomyopathy

AED

:    =  Automated External Defibrillators

BLS

:    =  Basic Life Support

CPR

:    =  Cardiopulmonary Resuscitation

ECG

:    =  Electrocardiogram

EMS

:    =  Emergency Medical Service

ERC

:    =  European Resuscitation Council

ESC

:    =  European Society of Cardiology

ICD

:    =  Implantable Cardioverter Defibrillator

ICU

:    =  Intensive Care Unit

IABP

:    =  Intra-Aortic Balloon Pump

LBBB

:    =  Left Bundle Branch Block

MRI

:    =  Magnetic Resonance Imaging

MTH

:    =  Mild Therapeutic Hypothermia

OHCA

:    =  Out-of-Hospital Cardiac Arrest

PCI

:    =  Percutaneous Coronary Intervention

PPCI

:    =  Primary Percutaneous Coronary Intervention

PEA

:    =  Pulseless Electric Activity

SCA

:    =  Sudden Cardiac Arrest

SCD

:    =  Sudden Cardiac Death

VF

:    =  Ventricular Fibrillation

VT

:    =  Ventricular Tachycardia

WPW

:    =  Wolf-Parkinson-White syndrome

![Algorithm for Advanced Life Support (ALS) \[21\].](CCR-9-316_F1){#F1}

![The chain of survival.](CCR-9-316_F2){#F2}

###### 

Causes of OHCA \[5-7\]

  Cardiac causes                                                                                                                                                                                                          Non-cardiac causes (≈5-12%)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------
   *Ischemia*(≈70%)  coronary artery disease (CAD) heart failure not related to CAD:coronary emboliinflammatory diseasevasospasm                                                                                          *Electrolyte disorders* Hypo-/hyperkalemiaacidosiskidney disease, dialysis
   *Structural heart disease* hypertrophic cardiomyopathydilated cardiomyopathy and heart failurearrhythmogenic right ventricular dysplasiaTakotsubo cardiomyopathymyocarditisaortic dissectioncongenital heart disease   *Neurological illnesses* strokesubarachnoid hemorrhage *Hypoxia* *Trauma (commotio cordis)* *Massive pulmonary embolism*
   *Electric disorders* Long-/short QT syndromeWolf-Parkinson-White syndrome (WPW)Brugada syndromeidiopathic                                                                                                              *Drugs and drug interactions* Digoxinantiarrhythmic drugsSeveral antidepressant drugs *Infectious diseases and sepsis*

###### 

Diagnostic Investigations for Patients After OHCA

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  History and physical examination Prior diagnoses of heart diseases, concomitant diseases?Family history?Medications (which could cause QT prolongation, electrolyte disorders, arrhythmia)Drug abuseAngina equivalent symptomsSigns of heart failure
  Laboratory evaluation  Electrolytes and renal function Blood gas including lactate and pH value, pO2 and pCO2 Serial troponin measurements, if no coronary angiography
  Electrocardiogram ST-segment elevation or new left bundle branch block (LBBB)2nd or 3rd degree heart blockSigns of Brugada, ARVC, long QT, WPW, hypertrophic cardiomyopathyPharmacologic challenge to reveal Brugada (procainamide) or polymorphic ventricular tachycardia (epinephrine)
  Echocardiography Structural heart disease (hypertrophic cardiomyopathy, ARVC,\...)LV-function and wall motion disturbances
  Coronary angiography Confirm/exclude ischaemia as underlying conditionAnomalous origin of the coronary arteries
  Cardiac magnetic resonance imaging LV-function, ischemiaStructural heart disease (ARVC, amyloidosis, sarcoidosis,...)Myocarditis
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Secondary Prevention of SCA. Decision Making on ICD Implantation

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reversible causes of OHCA\                                                                                   Non-reversible causes of OHCA\
  *ICD not primarily recommended*                                                                              *ICD recommended*
  ------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------
  Electrolyte disorders in the presence /or not of antiarrhythmic drug therapy proven to be the cause of SCA   LVEF \> 35%\
                                                                                                               Grey area\
                                                                                                               Electrophysiology studies potentially helpful\
                                                                                                               Individualised decision for ICD (hypertrophic cardiomyopathy, long QT, etc.)

  Arrhythmia related to acquired long QT syndrome\                                                              
  Patient must avoid exposure to drugs                                                                         

  Fulminant myocarditis                                                                                         

  WPW syndrome as a trigger for VF: ablation                                                                    
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
